<DOC>
	<DOC>NCT00978042</DOC>
	<brief_summary>Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.</brief_summary>
	<brief_title>Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation</brief_title>
	<detailed_description />
	<criteria>Male or female, 3565 years of age Zygomaticomalar region, anteromedial cheek, submalar region, and/or overall midfacial volume deficit assessed by the Treating Investigator as grade 3, 4, or 5 on the photometric MidFace Volume Deficit Scale (MFVDS) Desire cheek augmentation to correct agerelated volume deficit in the midface Accept the obligation not to receive any other facial procedures or treatments affecting facial volume deficit at any time during the study Received (or is planning to receive) anticoagulation, antiplatelet, or thrombolytic medications (e.g., warfarin), antiinflammatory drugs [oral/injectable corticosteroids or NonSteroidal AntiInflammatory Drugs (NSAIDs)], or other substances known to increase coagulation time from 10 days pre to 3 days post injection [Study device injections may be delayed as necessary to accommodate this 10day washout period.] Have undergone facial plastic surgery (with the exception of rhinoplasty more than 2 years prior to enrollment), tissue grafting, or tissue augmentation with silicone, fat, or other permanent, or semipermanent dermal fillers or be planning to undergo any of these procedures at any time during the study Have undergone temporary facial dermal filler injections with hyaluronic acidbased fillers within 12 months, porcinebased collagen fillers within 24 months, or neuromodulator injections, mesotherapy, or resurfacing within 6 months prior to entry in the study or be planning to undergo any of these procedures at any time during the study Have begun use of any new overthecounter or prescription, oral or topical, antiwrinkle products in the treatment area within 90 days prior to enrollment or be planning to begin use of such products at any time during the study. Have very thin skin in the midfacial region, tendency to accumulate fluid in the lower eyelids, or large infraorbital fat pads Have midface volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immunemediated diseases such as generalized lipodystrophy, partial lipodystrophy, inherited disease, or HIVrelated disease Have a history of anaphylaxis, multiple severe allergies, atopy, or allergy to lidocaine (or any amidebased anesthetic), hyaluronic acid products, or Streptococcal protein, or have plans to undergo desensitization therapy during the term of the study Have noticeable acne scarring, an active inflammation, infection, cancerous or precancerous lesion, or unhealed wound or have undergone radiation treatment in the area to be treated</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>